Free Trial
NYSE:BDX

Becton, Dickinson and Company (BDX) Stock Price, News & Analysis

$231.58
+0.31 (+0.13%)
(As of 09/18/2024 ET)

About Becton, Dickinson and Company Stock (NYSE:BDX)

Key Stats

Today's Range
$229.64
$235.04
50-Day Range
$225.00
$242.41
52-Week Range
$218.75
$269.52
Volume
1.12 million shs
Average Volume
1.42 million shs
Market Capitalization
$66.93 billion
P/E Ratio
51.01
Dividend Yield
1.64%
Price Target
$279.50
Consensus Rating
Moderate Buy

Company Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton, Dickinson and Company Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 96th Percentile

Becton, Dickinson and Company scored higher than 96% of companies evaluated by MarketBeat, and ranked 49th out of 1,015 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Becton, Dickinson and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Becton, Dickinson and Company has only been the subject of 4 research reports in the past 90 days.

  • Read more about Becton, Dickinson and Company's stock forecast and price target.
  • Earnings Growth

    Earnings for Becton, Dickinson and Company are expected to grow by 8.85% in the coming year, from $13.10 to $14.26 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Becton, Dickinson and Company is 51.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Becton, Dickinson and Company is 51.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.54.

  • Price to Earnings Growth Ratio

    Becton, Dickinson and Company has a PEG Ratio of 1.91. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Becton, Dickinson and Company has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Becton, Dickinson and Company's valuation and earnings.
  • Percentage of Shares Shorted

    0.69% of the float of Becton, Dickinson and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Becton, Dickinson and Company has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Becton, Dickinson and Company has recently increased by 33.78%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Becton, Dickinson and Company pays a meaningful dividend of 1.61%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Becton, Dickinson and Company has been increasing its dividend for 52 years.

  • Dividend Coverage

    The dividend payout ratio of Becton, Dickinson and Company is 83.70%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Becton, Dickinson and Company will have a dividend payout ratio of 26.65% next year. This indicates that Becton, Dickinson and Company will be able to sustain or increase its dividend.

  • Read more about Becton, Dickinson and Company's dividend.
  • Percentage of Shares Shorted

    0.69% of the float of Becton, Dickinson and Company has been sold short.
  • Short Interest Ratio / Days to Cover

    Becton, Dickinson and Company has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Becton, Dickinson and Company has recently increased by 33.78%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Becton, Dickinson and Company has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Becton, Dickinson and Company this week, compared to 9 articles on an average week.
  • Search Interest

    Only 3 people have searched for BDX on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Becton, Dickinson and Company to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Becton, Dickinson and Company insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.31% of the stock of Becton, Dickinson and Company is held by insiders.

  • Percentage Held by Institutions

    86.97% of the stock of Becton, Dickinson and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Becton, Dickinson and Company's insider trading history.

BDX Stock News Headlines

Kamala Harris and The Woke Progressive Nightmare
New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November.
Barclays Remains a Buy on Becton Dickinson (BDX)
See More Headlines

BDX Stock Analysis - Frequently Asked Questions

Becton, Dickinson and Company's stock was trading at $243.83 at the beginning of the year. Since then, BDX stock has decreased by 5.0% and is now trading at $231.58.
View the best growth stocks for 2024 here
.

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings results on Thursday, August, 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. The company's quarterly revenue was up 2.3% on a year-over-year basis.
Read the conference call transcript
.

Becton, Dickinson and Company subsidiaries include Cytognos, Scanwell Health Inc., Tissuemed Ltd., Venclose Inc., Tepha Inc., Velano Vascular, GSL Solutions, and more.

Top institutional shareholders of Becton, Dickinson and Company include Ameriprise Financial Inc. (1.75%), Massachusetts Financial Services Co. MA (1.70%), Bank of New York Mellon Corp (1.53%) and Clearbridge Investments LLC (1.03%). Insiders that own company stock include Thomas E Polen Jr, Claire Fraser, Roland Goette, Samrat S Khichi, Michael David Garrison, David Hickey, Richard Byrd, Thomas J Spoerel, Alexandre Conroy and Betty D Larson.
View institutional ownership trends
.

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Becton, Dickinson and Company investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), Walt Disney (DIS), Abbott Laboratories (ABT) and Intel (INTC).

Company Calendar

Ex-Dividend for 6/28 Dividend
6/10/2024
Dividend Payable
6/28/2024
Last Earnings
8/01/2024
Ex-Dividend for 9/30 Dividend
9/09/2024
Today
9/18/2024
Dividend Payable
9/30/2024
Fiscal Year End
9/30/2024
Next Earnings (Estimated)
11/14/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
07588710
Employees
73,000
Year Founded
1897

Price Target and Rating

Average Stock Price Target
$279.50
High Stock Price Target
$312.00
Low Stock Price Target
$255.00
Potential Upside/Downside
+20.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$1.48 billion
Pretax Margin
8.44%

Debt

Sales & Book Value

Annual Sales
$19.83 billion
Cash Flow
$20.03 per share
Book Value
$88.92 per share

Miscellaneous

Free Float
288,110,000
Market Cap
$66.93 billion
Optionable
Optionable
Beta
0.42

Social Links

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, September 8, 2024. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

  • Becton, Dickinson and Company has consistently increased its quarterly revenue, showing a positive growth trend.
  • The company's dividend payout ratio (DPR) is currently at 83.70%, indicating a stable dividend payment to shareholders.
  • Analysts have given a consensus rating of "Moderate Buy" with a target price of $279.50, suggesting potential for stock price appreciation.
  • Becton, Dickinson and Company's latest earnings per share (EPS) for the quarter exceeded analyst estimates, demonstrating strong financial performance.
  • The company's stock has a beta of 0.42, indicating lower volatility compared to the market, which may appeal to risk-averse investors.

Becton, Dickinson and Company
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

  • The company's quarterly revenue of $4.99 billion fell short of analyst estimates of $5.08 billion, potentially signaling a revenue growth challenge.
  • Becton, Dickinson and Company's stock price has experienced fluctuations, with a 1-year low of $218.75 and a 1-year high of $269.52, indicating price volatility.
  • Despite positive analyst ratings, there is a possibility of market uncertainties affecting the stock performance of Becton, Dickinson and Company.
  • The company's PEG ratio of 1.98 may suggest that the stock is currently overvalued based on its growth prospects.
  • Insiders have been selling company stock, with a recent transaction by a senior vice president, which could raise concerns among investors about future prospects.

This page (NYSE:BDX) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners